Skip Navigation
National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Personal tools
You are here: Home News Next Generation: Cancer Drug in Disguise
Navigation
 
Document Actions

Next Generation: Cancer Drug in Disguise

Researchers have modified a cytotoxic agent puromycin so that it remains inactive until it is exposed to certain cancer-related enzymes — HDACs and a protease known as cathepsin-L — both in vitro and in a mouse model, thereby enhancing the drug’s selectivity.  Reported in Nature Communications.

http://www.the-scientist.com/?articles.view/articleNo/38181/title/Next-Generation--Cancer-Drug-in-Disguise/